… nirmatrelvir/ritonavir. Three hospitalizations were recorded in the molnupiravir (2.1%) group
and one in the nirmatrelvir/ritonavir (… was 8 days in the nirmatrelvir/ritonavir group vs. 10 days …

… of molnupiravir and nirmatrelvir/ritonavir in … , nirmatrelvir/ritonavir significantly reduced
hospital admission by more than 20%, whereas molnupiravir did not reduce hospital admission of …

… Absolute risk difference in the incidence of hospitalization or death within 30 days among
individuals who did and did not receive nirmatrelvir/ritonavir. A, Inverse probability of treatment …

… with IgG positive had a shorter hospital stay (Figure 2H). We … of Nirmatrelvir‐ritonavir therapy
after disease onset in hospital stay of patients, and found that administration of Nirmatrelvir‐…

Background: Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral drug used to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in patients aged 12 years or older at high risk of …

… hospitals in South Korea from February 2022 to April 2022. A total of 236 patients in the
treatment group (administered nirmatrelvir-ritonavir… for not prescribing nirmatrelvir-ritonavir to the …

… could not be hospitalized due to a shortage of hospital beds. However, all patients requiring
hospitalization could be hospitalized in our hospital during this period. Second, we do not …

… and clinical severity of omicron COVID-19 appear to be weakened compared with previous
variants, it tends to evolve toward more transmissible, and the number of hospital admissions …

… This reduction with nirmatrelvir; ritonavir treatment was associated with hospital cost
savings equal to $133,754,359 per 100,000 patients. Sensitivity analyses, where the rate of …

… , hospital admission, and death, covering a period where both nirmatrelvir/ritonavir and …
was used as an exploratory comparator to nirmatrelvir/ritonavir, both of which were antivirals…